 BOSTON--BUSINESS WIRE--Ironwood Pharmaceuticals, Inc. NASDAQ: IRWD, a GI-focused healthcare company, today announced that The American Journal of Gastroenterology the official journal of The American College of Gastroenterology published full results from the companys Phase IIIb clinical trial evaluating LINZESS linaclotide 290 mcg on multiple abdominal symptoms in adult patients with irritable bowel syndrome with constipation IBS-C. The results, which can be viewed here, demonstr 